Phio Pharmaceuticals Corp. Files 8-K: Material Agreement & Equity Sales
Ticker: PHIO · Form: 8-K · Filed: Dec 26, 2024 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Dec 26, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $2.00, $0.48 m, $10,000, $2 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Phio Pharma inked a big deal & sold stock, filing details out now.
AI Summary
Phio Pharmaceuticals Corp. announced on December 23, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events, including financial statements and exhibits. The filing was made on December 26, 2024.
Why It Matters
This 8-K filing indicates significant corporate activity for Phio Pharmaceuticals, including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Registrant
- December 23, 2024 (date) — Date of earliest event reported
- December 26, 2024 (date) — Filing date
- 11 Apex Drive, Suite 300A, PMB 2006 (address) — Principal executive offices
- Marlborough, Massachusetts 01752 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Phio Pharmaceuticals Corp.?
The filing states that Phio Pharmaceuticals Corp. entered into a material definitive agreement on December 23, 2024, but the specific details of this agreement are not provided in the provided text.
When was the 8-K report filed with the SEC?
The 8-K report was filed on December 26, 2024.
What other types of events are reported in this 8-K filing?
Besides the material definitive agreement, the filing also reports on unregistered sales of equity securities and other events, as well as financial statements and exhibits.
What is the principal executive office address for Phio Pharmaceuticals Corp.?
The principal executive office address is 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, Massachusetts 01752.
What was Phio Pharmaceuticals Corp.'s former name?
Phio Pharmaceuticals Corp.'s former name was RXi Pharmaceuticals Corp., with a date of name change on October 19, 2011.
Filing Stats: 1,718 words · 7 min read · ~6 pages · Grade level 12.1 · Accepted 2024-12-26 16:05:08
Key Financial Figures
- $0.0001 — h registered: Common Stock, par value $0.0001 per share PHIO The Nasdaq Capital M
- $2.00 — "Common Stock"), at a purchase price of $2.00 per share. Pursuant to the Securities P
- $0.48 m — the Private Placement is approximately $0.48 million, after deducting fees and expense
- $10,000 — Offering and the Private Placement and $10,000 for non-accountable expenses, and $10,0
- $2 — arrants have an exercise price equal to $2.50, or 125% of the offering price per s
Filing Documents
- phio_8k.htm (8-K) — 39KB
- phio_ex0401.htm (EX-4.1) — 113KB
- phio_ex0402.htm (EX-4.2) — 113KB
- phio_ex0501.htm (EX-5.1) — 8KB
- phio_ex1001.htm (EX-10.1) — 257KB
- phio_ex9901.htm (EX-99.1) — 13KB
- image_003.jpg (GRAPHIC) — 3KB
- image_002.jpg (GRAPHIC) — 2KB
- 0001683168-24-008984.txt ( ) — 848KB
- phio-20241223.xsd (EX-101.SCH) — 3KB
- phio-20241223_lab.xml (EX-101.LAB) — 33KB
- phio-20241223_pre.xml (EX-101.PRE) — 24KB
- phio_8k_htm.xml (XML) — 4KB
02. Unregistered Sales of Equity Securities
Item 3.02. Unregistered Sales of Equity Securities. The disclosures in Item 1.01 of this Form 8-K regarding the Series F Warrants, the Warrant Shares, the Placement Agent Warrants and the shares of Common Stock issuable thereunder are incorporated by reference into this Item 3.02.
01. Other Events
Item 8.01. Other Events. On December 23, 2024, the Company issued a press release announcing the pricing of the Registered Direct Offering and the Private Placement. The full text of the press releases is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Number Description 4.1 Form of Series F Common Stock Warrant, dated December 24, 2024. 4.2 Form of Placement Agent Warrant, dated December 24, 2024. 5.1 Opinion of Hogan Lovells US LLP. 10.1 Form of Securities Purchase Agreement, dated December 23, 2024, by and between the Company and each of the Purchasers signatory thereto. 23.1 Consent of Hogan Lovells US LLP (contained in Exhibit 5.1). 99.1 Press Release issued by the Company on December 23, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHIO PHARMACEUTICALS CORP. Date: December 26, 2024 By: /s/ Robert Bitterman Robert Bitterman President & Chief Executive Officer 4